<- Go home

Added to YB: 2025-12-02

Pitch date: 2025-11-28

NOVO-B.CO [neutral]

Novo Nordisk A/S

-12.45%

current return

Author Info

No bio for this author

Company Info

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.

Market Cap

DKK 1.1T

Pitch Price

DKK 300.92

Price Target

N/A

Dividend

4.56%

EV/EBITDA

7.01

P/E

9.79

EV/Sales

3.73

Sector

Pharmaceuticals

Category

value

Show full summary:
Theodosian Capital | Stocks Update 28/11/2025 - NOVOB – Go Evoke, go broke

NOVO-B.CO (update): Evoke Alzheimer's drug failed Phase III trials, missing statistically significant reduction in disease progression. Heavy selloff despite weak prior sentiment. Trades at discounted 13.6x 2026 consensus earnings, 3.7% yield reflects lowered expectations.

Read full article (1 min)